Index Option Calls
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Index Option Calls
No Result
View All Result
Home Latest News

Pfizer says its Covid pill with HIV drug cuts the risk of hospitalization or death by 89%

by
November 5, 2021
in Latest News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Unusual Options Activity Scanner Reviews & Ratings: Top Picks for Traders

Alternative Investments Reviews & Ratings: A Comprehensive Guide to Diversifying Your Portfolio

A person walks past the Pfizer building in New York City, March 2, 2021.

Carlo Allegri | Reuters

Pfizer said Friday that its easy-to-administer Covid-19 pill, used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the virus.

It’s now the second antiviral pill behind Merck‘s to demonstrate strong effectiveness for treating Covid at the first sign of illness. If cleared by regulators, it would likely be a game changer in the ongoing global pandemic fight. Pfizer said it plans to submit its data to the Food and Drug Administration “as soon as possible.”

Pfizer’s pill, scientifically known as PF-07321332, is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme the virus needs to replicate in human cells. Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.

The HIV drug helps slow the metabolism, or breakdown, of Pfizer’s pill in order for it to remain active in the body for longer periods of time at higher concentrations, the company said.

The company said its data on the drug is based on a mid-to-late stage study of 1,219 adults who had at least one underlying medical condition and a laboratory-confirmed infection within a five-day period. Participants were also given a low dose of ritonavir, a medication commonly used in combination treatments for HIV.

Pfizer said there were six hospitalizations and zero deaths out of the 607 trial participants who received the pill in combination with the HIV drug within five days of symptom onset. That compares with 41 hospitalizations and 10 deaths out of the 612 people who received a placebo.

“These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer CEO Albert Bourla said in a statement.

Unlike Gilead Sciences‘ intravenous drug remdesivir, Pfizer’s and Merck’s drugs can be taken by mouth. While vaccinations remain the best form of protection against the virus, health experts hope pills like these will keep the disease from progressing in those who do get infected and prevent trips to the hospital.

Merck and Ridgeback Biotherapeutics said Oct. 1 that they’ve developed a drug that, when administered alone, reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid.

The antiviral pill made by Merck was approved by Britain’s medicines regulator on Thursday.

June Raine, chief executive of the U.K.’s Medicines and Healthcare products Regulatory Agency, said that Merck’s pill will greatly facilitate the treatment of Covid, a disease that has killed more than 5 million people globally and caused tremendous strain on health systems.

Bourla told CNBC in April that Pfizer’s pill could be available to Americans by the end of this year.

ShareTweetPin

Related Posts

Unusual Options Activity Scanner Reviews & Ratings: Top Picks for Traders

by
September 21, 2023
0

One of the key indicators savvy options traders often watch is unusual options activity. This term refers to the sudden...

Alternative Investments Reviews & Ratings: A Comprehensive Guide to Diversifying Your Portfolio

by
September 21, 2023
0

Alternative investments are financial assets outside traditional investment categories like stocks, bonds, and cash. These include real estate, art, wine,...

AI Stock Trading Software Reviews & Ratings: A Comprehensive Guide to the Top Platforms

by
September 21, 2023
0

AI in stock trading brings unprecedented automation and precision to the table. It’s capable of analyzing vast amounts of data...

Trading Journal Software Reviews & Ratings: Navigating the Best Options

by
September 21, 2023
0

A trading journal serves as a record-keeper and a performance analyzer. It provides traders invaluable insights into their trading habits,...

Thursday: Existing Home Sales, Unemployment Claims, Philly Fed Mfg

by
September 21, 2023
0

by Calculated Risk on 9/20/2023 08:36:00 PM Note: Mortgage rates are from MortgageNewsDaily.com and are for top tier scenarios. Thursday:...

Next Post

Chart analysts are watching market's big rally since mid-October for signs of exhaustion

Insider buying: Big moves from Intel leaders highlight this week's top-five internal stock purchases

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • A Couple Stored IRA Gold at Home. They Owe the IRS More Than $300,000.

    0 shares
    Share 0 Tweet 0
  • A California Couple Spent Eight Years Building Their Dream Retirement Home in Costa Rica

    0 shares
    Share 0 Tweet 0
  • Goldman Sachs picks new stocks to buy — and says these 5 have over 100% upside

    0 shares
    Share 0 Tweet 0
  • Goldman Sachs says buy these stocks to play Web 3.0 and the metaverse

    0 shares
    Share 0 Tweet 0
  • In his final warning, this stock trading wizard — who made big money in bear markets and crashes — called this market a bubble like no other

    0 shares
    Share 0 Tweet 0
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.indexoptioncalls.com
No Result
View All Result
  • Home
  • Latest News
  • Email Whitelisting
  • Privacy Policy

All rights reserved by www.indexoptioncalls.com